Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| It is designed for long-term growth and basically has capacity, which is three times our previous one, which is very good for long-term potential and the margin |
| Our expectation is that we will continue trending towards cash flow breakeven, and our belief that trends towards operating leverage will allow us to maintain a strong balance sheet position and provide ample support as we work towards profitability |
| So we were really pleased across all of the areas and with all of our products |
| We're pleased with our performance during the quarter |
| 2023 was a solid year of key accomplishments, and we entered 2024 with a strong commercialization strategy, fueled by innovation and focused execution by our sales team |
| We're encouraged by the positive interactions and have aligned with the FDA on a rolling submission process and the content of the modules for submission |
| In the back half of 2023, we saw improved commercial execution, and during this period, we estimate that revenue from our emerging trauma procedures grew in the mid-single digits, and revenue from scheduled procedures grew above 25% as compared to the same period in 2022 |
| We're pleased with our progress and execution as we drive long-term growth, leveraging innovation, clinical data, surgeon education and patient activation |
| In the future, we expect our gross margin to benefit from improved capacity utilization of our new processing facility as our sales volume of Avance increases |
| We're confident that AxoGuard HA+ will expand the adoption of nerve protection products and will help more patients with nerve injuries |
| We also saw strong surgeon and patient interest in neurotization and implant-based breast reconstruction and expanded the number of surgical teams trained in this important new application |
| And in summary, we're pleased with our fourth quarter performance |
| We're pleased with the surgeon engagement, positive feedback from our educational programs, and the early adoption of this new technique |
| We were pleased by the contributions from innovations in new products and new applications |
| I'm very excited about the AxoGen story and the potential of the company |
| And then long term, definitely, we expect the margin to benefit from higher sales, higher production and higher capacity utilization |
| With over 100,000 Avance Nerve Grafts implanted since launch, we are well positioned to continue to lead and innovate in the large and developing peripheral nerve repair market |
| Strength in this category reflects the opportunity to provide improved quality of life outcomes for patients, compelling clinical data, effective surgeon education and implementation of patient activation programs |
| We believe Avive+ will be regulated as a Section 361 tissue product and will further strengthen our position in nerve protection, supporting emergent trauma and the surgical treatment of pain |
| This study adds to a strong pool of clinical evidence supporting Avance Nerve Graft |
| This January, we announced positive top line results from the REPOSE clinical study, comparing the standard-of-care neurectomy of symptomatic neuroma to neurectomy and protection of the terminated nerve end with AxoGuard Nerve Cap |
| And we've seen continued enthusiasm for that growth and expansion in -- as we've entered here into Q1 |
| You saw a great growth in the scheduled procedures in 4Q |
| So we have a very good pool to continue to build from as we drive those core accounts and build a bigger base |
| Revenue growth and benefit of the operational leverage and the economies of scale, I think this is the most important thing |
| So we're looking at continuing to see measured growth through the year, driven predominantly by productivity improvements with our existing sales team |
| Again, so far, we've been pleased how we saw the beginning of the year, but we're wanting not to get out over our skis on this |
| I'm proud of our team, and I look forward to continuing our mission of revolutionizing the science of nerve repair |
| In addition, the study investigators found that over the full 12-month course of follow-up, AxoGuard Nerve Cap demonstrated statistical superiority for reduction in total pain reported by the subjects as compared to the standard of care neurectomy |
| So we continue to see be interested in how they're using it, seeing some great applications in those areas where they want to have that gliding surface and getting some very positive feedback about the product |
| Statement |
|---|
| This represents gross margin of 78.7%, down from 83% in the same period last year |
| The guidance is a little bit lower than what we were thinking |
| Just to start with 2024 guidance, it seems to imply a deceleration year-over-year at the midpoint, even though it seems like scheduled procedure growth has seemed to tick up |
| There is some cannibalization |
| Adjusted fourth quarter EBITDA was $0.6 million compared to an adjusted EBITDA loss of $0.7 million in the prior year |
| And this is one of the drivers for the lower margin |
| However, we recorded an adjusted net loss of $2.6 million for the quarter, translating to roughly $0.06 per share, a shift from an adjusted net loss of $1.1 million or $0.03 per share in the same period last year, driven in part by one-time severance costs |
| So this is why the second year might be a bit lower |
| The quarter ended with a net loss of $3.9 million or $0.09 per share, compared to a net loss of $5.4 million or $0.13 per share in the fourth quarter of 2022 |
| We expect the margin probably in the later half of the year to be on the lower side versus the first half of the year |
| General and administrative expenses decreased by 16.3% to $7.5 million in Q4 of 2023 from $8.9 million in Q4 of 2022, driven mainly by [its stock on forfeitures] (ph) due to the departure of executives from our company |
| And then it was basically flat to down in fourth quarter, and then sequentially, again, flat to down into the first quarter of the next year |
| I was wondering if you can make any comment on sort of what you think that EBITDA loss might look like or maybe compared to what '23 was directionally? Any help there would be great |
| As a percentage of total revenues, total R&D expenses reduced to 17%, down from 18.8% in the last quarter of the previous year |
| So just to confirm, we should expect sequential decreases in gross margin through the year? Not a first half dip and then a second half rebound? Nir Naor Right |
Please consider a small donation if you think this website provides you with relevant information